BMO Capital Initiates Coverage on Neos Therapeutics Inc(NASDAQ:NEOS). The shares have been rated Outperform. The rating by BMO Capital was issued on Jun 29, 2016.
Neos Therapeutics Inc(NEOS) last announced its earnings results on May 16, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $2.58M. Analysts had an estimated revenue of $1.07M. Earnings per share were $-0.79. Analysts had estimated an EPS of $-0.86.
Several Insider Transactions has been reported to the SEC. On Jun 14, 2016, Juergen Martens (Chief Tech/Operations Officer) purchased 10,000 shares at $9.90 per share price.Also, On May 19, 2016, Thomas P Mcdonnell (Chief Commercial Officer) purchased 3,000 shares at $7.56 per share price.On May 19, 2016, Alan L Heller (director) purchased 10,000 shares at $7.61 per share price, according to the Form-4 filing with the securities and exchange commission.
Neos Therapeutics Inc. is a pharmaceutical company develops manufactures and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The Companys product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It manufactures and markets generic Tussionex a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD and NT-0201 amphetamine XR liquid suspension for the treatment of ADHD. The company is headquartered in Grand Prairie Texas.